



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/074,302	02/11/2002	Peter Colosi	0800-0005.05	8094
31048 7:	590 12/21/2004		EXAMINER	
ROBINS & PASTERNAK LLP 1731 EMBARCADERO ROAD			KATCHEVES, KONSTANTINA T	
SUITE 230			ART UNIT	PAPER NUMBER
PALO ALTO,	CA 94303		1636	

DATE MAILED: 12/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/074,302	COLOSI, PETER			
Office Action Summary	Examiner	Art Unit			
•	Konstantina Katcheves	1636			
The MAILING DATE of this communication ap	1				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)⊠ Responsive to communication(s) filed on 28 July 2004.					
•					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-5,7-11,13,15 and 16 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed.  6) Claim(s) 1-5, 7-11, 13, 15 and 16 is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
<ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment/s)					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Di  5) Notice of Informal F  6) Other:	(PTO-413) ate Patent Application (PTO-152)			

Art Unit: 1636

#### **DETAILED ACTION**

Claims 1-5, 7-11, 13, 15 and 16 are pending in the present application.

## Response to Amendment

The rejection of claims 1-5, 7-11, 13, 15 and 16 under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 2, 4, 5, 6, 8, 3, 7, 9, 10, 24, 15, 16, 20, 11, 17, 12, 18, 21, 22, 23, 25, 19, 24 and 13, respectively, of prior U.S. Patent No. 6,001,650 has been withdrawn in view of Applicant's amendment.

Claims 1-5, 7-11, 13, 15 and 16 stand rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 6,376,237.

Claims 1-5, 7-11, 13, 15 and 16 stand rejected under obviousness-type double patenting over claims 1, 2, 7, 8 and 12-15 of U.S. Patent No. 6,365,403. Applicant has asked that this rejection be held in abeyance until allowable subject matter is noted.

The double patenting rejections over claims 26-41 are withdrawn in view of the cancellation of these claims.

## Response to Arguments

Applicant's arguments filed 28 July 2004 have been fully considered but they are not persuasive.

Claims 1-5, 7-11, 13, 15 and 16 stand rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No.

Art Unit: 1636

6,376,237. Applicant argues that the '237 patent does not claim a methods of making rAAV stocks. The claims of the '237 are product by process claims and thereby do claim methods of making rAAV such that the present claims would have been obvious to those of ordinary skill in the art for the reasons already of record. These claims are appropriately rejected under the doctrine of obviousness-type double patenting.

# New Grounds of Rejection Necessitated by Applicant's Amendment Double Patenting

Claims 1-5, 7-11, 13, 15 and 16 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 and 15-25 of U.S. Patent No. 6,001,650.

The present claims are drawn to a nucleic acid molecule which encodes one or more AAV helper functions wherein said functions are found in 5' to 3' order. The '650 patent disclose such a nucleic acid molecule however does not specify in which order these components are found. The components of the nucleic acid molecule comprise coding regions which provide necessary AAV helper functions. One of ordinary skill in the art would have been motivated in view of the '650 patent to make a nucleic acid molecule with these coding regions regardless of the order they are found in or expressed. Once these elements are expressed the helper functions are inherent in whether or not the coding sequences are found in any particular order. Therefore, the invention as a whole would have been *prima facie* obvious to one of skill in the art.

Art Unit: 1636

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konstantina Katcheves whose telephone number is (571) 272-0768. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday 7:30 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konstantina Katcheves Examiner Art Unit 1636

> JAMES KETTER PRIMARY EXAMINER